Abstract:Jing Huang, 1, &ast Mengmeng Dai, 1, &ast Mingxia He, 1, &ast Weicheng Bu, 1 Liwen Cao, 1 Jing Jing, 1 Run Cao, 1 Hailong Zhang, 1 Ke Men 2 1 Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, Henan University, Kaifeng, Henan Province, 475004, People's Republic of China; 2 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, 610044, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hailong Zhang, Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, Henan University, Kaifeng, Henan Province, 475004, People's Republic of China, Email Ke Men, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, 610044, People's Republic of China, Email Purpose: The abnormal activation of NLRP3 inflammasome is related to the occurrence and development of ulcerative colitis (UC). However, the ideal drug and delivery system remain important factors limiting the targeting of NLRP3 inflammasome in UC therapy. Gene therapy by delivering siRNA is effective in treating various diseases. Therefore, delivering siNLRP3 using an ideal vector for UC treatment is necessary. Materials and Methods: Nanoparticles delivering siNLRP3 were developed based on cationic liposome (CLP/siNLRP3). Their ability to inhibit NLRP3 inflammasome activation was monitored using Western blot (WB) and Enzyme-linked Immunosorbent Assay (ELISA). The ASC oligomerization in LPS-primed peritoneal macrophages (PMs) was detected by WB and immunofluorescence. Moreover, we assessed the role of CLP/siNLRP3 on dextran sodium sulfate (DSS)-induced UC by examining NLRP3 levels, pro-inflammatory cytokines expression, and disease-associated index (DAI). Flow cytometry (FCM) was used to detect the contents of macrophages and T cells. Finally, we assessed the safety of CLP/siNLRP3. Results: The prepared CLP was spherical, with a small particle size (94 nm) and low permeability. The CLP could efficiently protect siNLRP3 from degradation and then deliver siNLRP3 into PMs, inhibiting NLRP3 inflammasome activation. Also, the CLP/siNLRP3 could inhibit the secretion of mature IL-1β and IL-18 from PMs, thereby achieving a favorable anti-inflammation effect. In vivo, CLP/siNLRP3 could effectively alleviate intestinal injury in UC mice, which was attributed to down-regulating levels of IL-1β and IL-18, inhibiting infiltration of macrophages and other immune cells, and the polarization of M1 macrophages. Finally, pathological testing of tissue sections and blood biochemical tests showed no significant toxic effects of CLP/siNLRP3. Conclusion: We introduced a prospective approach for the efficient delivery of siRNA in vitro and in vivo with high safety and stability, which was found to have great potential in treating NLRP3-driven diseases in an RNA-silencing manner. Keywords: cationic liposome, NLRP3, siRNA, macrophage, ulcerative colitis Since the 20th century, tThe incidence of ulcerative colitis (UC) has been increasing over time, negatively affecting peoples' health. 1,2 UC is a multifactorial induced inflammatory bowel disease (IBD) characterized by chronic recurrent and remitting mucosal inflammation. 3,4 It originates in the rectum and then extends to the proximal segments of the colon. 5,6 If not timely and adequately treated, it can lead to persistent intestinal damage and an increased risk of hospitalization, surgery, and even colon cancer. 7–9 Considering no radical treatment is available, patients with UC must take life-long medications. 10 Therefore, it is an urgent problem for patients and society to find ideal targets and therapeutic strategies for UC based on mechanism studies. The pathogenesis of UC is complex. Studies have suggested that the susceptibility of UC to intestinal mucosal damage results from a disturbed innate immune response. 11,12 Therefore, the modulation of the innate immune response in the intestine may be crucial for treating UC. The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is an important contributor to macrophage activation and immune response, composed of the core molecule NLRP3, the adapter apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and the effector molecule pro-caspase-1. 13–15 When sensitized to damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) -Abstract Truncated-

Targeting of NLRP3 Inflammasome with Gene Editing for the Amelioration of Inflammatory Diseases

Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles

Optimization of Lipid-Assisted Nanoparticle for Disturbing Neutrophils-Related Inflammation

Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing Tool

Inflammation Conditional Genome Editing Mediated by the CRISPR-Cas9 System

Immunometabolic reprogramming of macrophages with inhalable CRISPR/Cas9 nanotherapeutics for acute lung injury intervention

Targeted Macrophage CRISPR-Cas13 Mrna Editing in Immunotherapy for Tendon Injury

Lipid Nanoparticle-Mediated Gene Editing of Human Primary T Cells and Off-Target Analysis of the CRISPR-Cas9 Indels

Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model

Abstract 528: Towards Therapeutic Genome Editing in Vascular Endothelium by Novel Nanoparticle Delivery of Crispr Plasmid Dna

Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis

The Strategies of Targeting the NLRP3 Inflammasome to Treat Inflammatory Diseases.

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases

Genome-editing prodrug: Targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

Treatment of Ulcerative Colitis by Cationic Liposome Delivered NLRP3 siRNA